Replies to post #120 on Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

Additional immune checkpoint targets, cytokine tethered TIL, as well as transient and stable gene insertion and inactivation are being developed. Also, PD-1+ selected TIL (in a trial), CD39/69 double negative TIL [1], Gen 3 (16 day) manufacturing (in a trial), core biopsy (in a trial) [2] and an IL-2 analog.

Refs:
1 https://www.iovance.com/wp-content/uploads/Iovance_ESMO-IO-2021_AKTi-TIL-Expansion.pdf
2 https://www.iovance.com/wp-content/uploads/Iovance_SITC2019_Poster_Core_20191102_FINAL_DE.pdf

[jondoeuk]

Preclinical data https://www.iovance.com/wp-content/uploads/IovanceBio-ESMO_Poster_1_KritR-v14_20200831a.pdf

Additional will be presented at AACR (next month).